In-vitro evaluation of dendrimeric formulation of oxaliplatin

Basit Öğe Kaydı
dc.authoridGedik, Gülşah/0000-0003-4147-6729
dc.authorwosidGedik, Gülşah/GWC-6445-2022
dc.contributor.authorNazli, Hakan
dc.contributor.authorGedik, Gulsah
dc.date.accessioned2024-06-12T11:11:53Z
dc.date.available2024-06-12T11:11:53Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThe aim of this study is, preparing various dendrimeric formulations of oxaliplatin and investigating their properties. First of all, the solubility enhancement capabilities of polyamidoamine (PAMAM) G3.5 and PAMAM G4.5 dendrimers were investigated. The results showed that oxaliplatin solubility mostly increasing linearly with dendrimer concentration. Additionally, the increase was more notable in PAMAM G4.5 dendrimers. Then, drug-dendrimer complexes were prepared in different mediums, since the medium used can affect the amount of drug-loaded to dendrimers. Prepared complexes were examined for loading capacity and loading efficiency. It was found that PAMAM G4.5 dendrimers can complex with 2- to 5-fold more oxaliplatin than PAMAM G3.5. Finally, oxaliplatin was modified to a platinum (IV) compound to prepare chemical drug-dendrimer conjugates. Ester bonds were established by Steglich esterification through the hydroxyl group of modified oxaliplatin and the carboxyl groups of the dendrimers. The formulations were characterized by UV, IR, NMR spectroscopy, and dynamic light scattering techniques. PAMAM G3.5 conjugate was further evaluated for the cytotoxicity test. The IC50 value of PAMAM G3.5 conjugate was found as 0.72 mu M. For unmodified oxaliplatin, this value was 14.03 mu M. As a result, a dendrimer-based drug delivery system that has been found promising for further improvement has been developed successfully.en_US
dc.description.sponsorshipTrakya University Scientific Research Projects Unit [2016/165]en_US
dc.description.sponsorshipThis work was supported by Trakya University Scientific Research Projects Unit [2016/165].en_US
dc.identifier.doi10.1080/10837450.2021.1944205
dc.identifier.endpage764en_US
dc.identifier.issn1083-7450
dc.identifier.issn1097-9867
dc.identifier.issue7en_US
dc.identifier.pmid34154500en_US
dc.identifier.scopus2-s2.0-85109010191en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage750en_US
dc.identifier.urihttps://doi.org/10.1080/10837450.2021.1944205
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22969
dc.identifier.volume26en_US
dc.identifier.wosWOS:000668065000001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofPharmaceutical Development And Technologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOxaliplatinen_US
dc.subjectDendrimeren_US
dc.subjectPoly(Amidoamine)en_US
dc.subjectColon Canceren_US
dc.subjectSolubility Enhancementen_US
dc.subjectDrug-Dendrimer Interactionsen_US
dc.subjectColorectal-Canceren_US
dc.subjectPoly(Amidoamine) Dendrimersen_US
dc.subjectPolyamidoamine Dendrimeren_US
dc.subjectPlatinum(Iv) Complexesen_US
dc.subjectPamam Dendrimersen_US
dc.subjectCarbon Nanotubesen_US
dc.subjectSolubilityen_US
dc.subjectDeliveryen_US
dc.subjectReleaseen_US
dc.subjectPhen_US
dc.titleIn-vitro evaluation of dendrimeric formulation of oxaliplatinen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu